Pegaptanib for myopic choroidal neovascularization in a young patient
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The treatment of choroidal neovascularization (CNV) due to myopic degeneration can include laser photocoagulation, photodynamic therapy, corticosteroids, and subretinal surgery. We report a case of a young patient with myopic CNV refractive to laser photocoagulation, photodynamic therapy, and intravitreal triamcinolone acetonide treated with intravitreal pegaptanib injections.
Interventional case report. The medical chart of a 36-year-old female treated with intravitreal pegaptanib injections was reviewed for changes in visual acuity on the Early Treatment of Diabetic Retinopathy Study (ETDRS) chart, CNV leakage on fluorescein angiography, and adverse events reported.
ETDRS visual acuity improved from counting fingers (CF) to 20/40 in the right eye after five, 6-weekly pegaptanib injections.
This is the sentinel case of US Food and Drug Administration (FDA) approved pegaptanib usage for non-wet macular degeneration via an Investigational New Drug application (Title 21, Code of Federal Regulations part 132). Pegaptanib appears to be effective in treating myopic CNV refractive to laser photocoagulation, photodynamic therapy, and intravitreal triamcinolone acetonide.
- Yoshida T, Ohno-Matsui K, Ohtake Y, Takashima T, Futagami S, Baba T, Yasuzumi K, Tokoro T, Mochizuki M (2002) Long-term visual prognosis of choroidal neovascularization in high myopia. A comparison between age groups. Ophthalmology 109(4):712–719 CrossRef
- Chan W-M, Lam DSC, Wong T-H, Lai TYY, Kwok AKH, Tam BSM, Li KKW (2003) Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization: one-year results from a prospective case series. Ophthalmology 110(12):2395–2402 CrossRef
- Macular Photocoagulation Study Group (1982) Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial. Arch 101(9):1358–1361
- Gragoudas ES, Adamis AP, Cunningham ET Jr,Feinsod M, Guyer DR; VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group (2004) Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351(27):2805–2816 CrossRef
- Pegaptanib for myopic choroidal neovascularization in a young patient
Graefe's Archive for Clinical and Experimental Ophthalmology
Volume 245, Issue 6 , pp 903-905
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Myopic choroidal neovascularization
- Pegaptanib sodium
- Industry Sectors